R&D Insight

Perspectives on restoring the antibiotic ecosystem: ACS ID, June 2020 issue

Dear All, The June issue of ACS Infectious Diseases (link) is entirely devoted to the perspectives on how we can restore and maintain the antibiotic ecosystem. Check it out … we have perspectives from major groups driving policy, groups doing active R&D, and the major funders. Here’s the table of contents, re-organized slightly to group

Read More »

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

Read More »

Climate change and AMR: NIH grant opportunity!

Dear All, A Notice of Special Interest (a “NOSI” in NIH jargon; here’s the link: NOT-ES-22-006) from the NIH could be something of interest for AMR R&D. This NOSI has > 10 of the Institutes behind it and as summarized on the website “this NOSI encourages applications that address the impact of climate change on health

Read More »

WHO Collaborating Centres for AMR: A rapidly growing group!

Dear All, I recently learned about the designation of Stanford as a WHO Collaborating Centre (WHOCC) for AMR and Stewardship. This caused me to dig a bit more into the way that WHO has created a global network of Collaborating Centres. WHOCC designation represents a sustained and productive collaboration with WHO (link). As an example, Stanford’s

Read More »

NIAID Small Business Application Assistance Program seeks applications!

Dear All, National Institute of Allergy and Infectious Diseases (NIAID) put out a call on 22 Oct 2020 for applications for its Applicant Assistance Program (AAP). The AAP provides no cost support for US-based companies planning to apply for a Phase II, Fast Track, or Direct-to-Phase II Small Business Innovation Research (SBIR) or Small Business Technology

Read More »

G7 Health ministers 3-4 June communique / Implications for choosing wisely

Note: Newsletter now updated to include the communique from the G7 Finance Ministers! Dear All, The G7 met in Oxford this past week and we now have communiques released from by both the Health and Finance Ministers. Let’s look first at the two fascinating statements from the Health Ministers: A general communique that includes multiple

Read More »

PASTEUR Act re-introduced and levels up antimicrobial economics for strong innovation!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Woot, woot! Woot, woot! US Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) have today reintroduced the PASTEUR (Pioneering Antimicrobial Subscriptions to End Up surging Resistance) Act! Here are the links you need: The text of

Read More »

Ways to talk about AMR / Video chat with Maryn McKenna

Dear All, Explaining AMR to our colleagues is not easy! I wrote in a 30 Oct 2019 newsletter about what Wellcome Trust learned on this point when they interviewed 12,000 people in Germany, India, Japan, Kenya, the UK, the USA and Thailand — in brief, there are universal themes that improve the likelihood that your message will

Read More »
Scroll to Top